ICMHI 2022

Keynote Speakers

 

 

Prof. Dr. Tomohiro Matsuda,
President of the International Assoc. of Cancer Registries (IACR), 2017-2019, WHO

Dr. Tomohiro Matsuda was born in Tokyo, Japan in 1973. After graduating Kobe University (1996) and Tokyo University (1998), he moved to France as a doctoral student in Paul Sabatier University in Toulouse. He joined Tarn cancer registry, and received a doctoral degree in epidemiology (2003). Dr. Matsuda landed a position of researcher in the Division of Epidemiology in the National Institute of Public Health in Japan.

Currently Dr. Matsuda works in the National Cancer Center in Tokyo as chief of the national cancer registry section, while pursuing research in descriptive cancer epidemiology, especially in incidence and survival comparison. Since 2006, he has managed a project to standardize registration methods and played a key role in enacting the Act on Promotion of Cancer Registries (2013). Dr. Matsuda has been involved in international cancer registration training programs in Korea, China, Malaysia, Indonesia, Philippines, Myanmar, etc. and in the GICR project as the director of the IARC Collaborating Center in Japan. Dr. Matsuda has been the president of the International Association of Cancer Registries, IACR, since 2016 enhancing the capacity of cancer registries worldwide.

 

Speech Title "Cancer Research Collaboration in Asia: Establishing clinical trials"

Some cancers that are unique in Asia, such as gastric cancer, liver and biliary tract cancer. If the "global market" of clinical trials is led by Europe and the U.S., not only will such unique cancers not receive attention, but also the trials in Asian countries will be delayed, resulting in drug lag. It is necessary for Asia to take the lead in drug development tailored to the region. The Ministry of Health, Labor and Welfare and PMDA are building a cooperative system with the regulatory authorities of Asian countries based on the conclusion of MOUs. In this field, "physician-led clinical trials" for new drugs is particularly important. The National Cancer Center Japan (NCCJ) is serious about conducting international clinical trials with high-level medical institutions in East Asia. The Asian Oncology Early Phase 1 Consortium, a consortium consisting of five medical institutions in China, Hong Kong, Taiwan, Singapore, and South Korea, is a perfect example of such joint implementation of early clinical trials (Phase 1 trials). LC-SCRUM-Asia, led by the NCC Hospital East, is expanding its genetic screening infrastructure to other Asian countries with the aim of establishing personalized medicine for lung cancer. As a result of the RARECAREnet Asia study, the percentage of rare cancers in Japan is 16.4%, and the number of cases is approximately 16,000 per year. In order to attract attention to such rare cancers, collaboration in Asia is essential. With the establishment of the Asian Partnerships Office of NCCJ, it is necessary to support the development of medical systems and provide trainings to the national cancer centers and oncology hospitals in the countries where clinical trials are not yet in place.

 

 Prof. Dr. Yung-Po Liaw
Department of Public Health, Chung Shan Medical University, Taiwan

Professor Yung-Po Liaw (https://jrain1005.wixsite.com/liawypen) graduated from National Taiwan University with a master's degree in biostatistics and a doctorate in epidemiology. Yung-Po Liaw currently works at the department of public health and institute of public health, Chung Shan Medical University., Research interests include spatio-temporal mapping of cancer in Taiwan, big data analysis of epidemiology, and precision public health research. The big data used include Taiwan Biobank Database, National Health Insurance Research Database, National Cancer Registry and National Death Database. Our research team constructed a 40-year spatio-temporal cancer map (http://Taiwancancermap.csmu-liawyp.tw/) in Taiwan, and also focused on precision public health research related to GWAS, SNP, HLA, and methylation. Our team is looking forward to cooperating with researchers from all over the world. Work together to explore interesting scientific topics

 

Speech Title "Taiwan cancer map"

Cancer has been listed as one of the top causes of death in Taiwan for many years. The burden of cancer is substantial and affects both medical care and public health, not only in Taiwan but all over the world. The construction of the Cancer Map will help in establishing cancer etiology. Generating cancer hypotheses through cancer maps could reduce the cancer incidence, thereby reducing the associated burden.
Taiwan Cancer Map is a spatio-temporal map showing cancer mortality in Taiwan. Mortality data will be obtained from the National Death Databank of the Bureau of Health Promotion, Department of Health, Executive Yuan. The map presents the spatio-temporal variation in age-standardized mortality of various cancers in every township in Taiwan. In this talk, we will show the spatio-temporal cancer map of Taiwan and its application.